glp-1 medication cost with insurance 68% of Users Say Influenced Their Treatment Decisions Why are GLP-1 medications so
Description
In expanded populations, comparing semaglutide versus sitagliptin for the composite outcome of myocardial infarction or stroke yielded a hazard ratio of 0.82 (95% confidence interval (CI) 0.74 to 0.91), and comparing tirzepatide versus dulaglutide for the composite outcome including mortality yielded a hazard ratio of 0.87 (95% CI 0.75 to 1.01)
Companies that make GLP-1 drugs urged patients to use the medications as intended
J Clin Endocrinol Metab 2003;88:2706-13.ArticlePubMed 95
Under this model, CMS will negotiate drug pricing and coverage terms on behalf of state Medicaid agencies and Medicare Part D plan sponsors
this increases GLP-1 as well
It looks like a classical Win/Win model
